PharmaShots | Incisive News in 3 Shots

Subscribe Now

Marginal Zone

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

February 2, 2021

Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults

Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults

May 29, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us